Table 1.
MIC determination for selected mutants against different beta-lactams.
| Mutants | Ancestral allele | Ancestral mutation | Acquired mutations | MIC (mg/L) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | CEP | FAZ | FOX | AXO | CTX | POD | FEP | CAZ | CZA | T/C | MEM | IMP | PTZ | F/C | FDC | ||||
| KPC-2 | – | – | > 16 | > 16 | > 16 | 16 | 32 | 16 | > 32 | 4 | 16 | 0.5 | 16 | 4 | 2 | > 64 | 2 | 0.25 | |
| KPC-3 | – | H274Y | > 16 | > 16 | > 16 | 16 | 32 | 16 | > 32 | 8 | 64 | 1 | 32 | 4 | 2 | > 64 | 4 | 0.12 | |
| KPC-33 | – | D179Y | < 8 | 16 | < 8 | 8 | 8 | 4 | 8 | < 1 | 128 | 24 | 2 | < 1 | < 0.5 | < 4 | < 0.12 | 2 | |
| KPC-2n2 | KPC-2 | – | D179Y D209V | < 8 | > 16 | < 8 | 8 | 8 | 4 | 16 | < 1 | 128 | 32 | 2 | < 1 | < 0.5 | < 4 | 0.5 | > 32 |
| KPC-3n4 | KPC-3 | H274Y | L169P | 16 | 16 | < 8 | 8 | 8 | 4 | 16 | 2 | > 128 | 12 | 2 | < 1 | < 0.5 | < 4 | < 0.12 | 2 |
| KPC-33n6 | KPC-33 | D179Y | R6H F20L | < 8 | 16 | < 8 | 8 | 8 | 8 | 16 | < 1 | > 128 | 64 | 2 | < 1 | < 0.5 | < 4 | < 0.12 | 8 |
| plasmid KPC-2n2 in naïve E. coli Top10 | KPC-2 | – | D179Y D209V | < 8 | > 16 | < 8 | 8 | 8 | 4 | 16 | < 1 | 128 | 32 | 2 | < 1 | < 0.5 | < 4 | 0.25 | 2 |
| plasmid KPC-3n4 in naïve E. coli Top10 | KPC-3 | H274Y | L169P | 16 | 16 | < 8 | 8 | 8 | 4 | 16 | 2 | > 128 | 12 | 2 | < 1 | < 0.5 | < 4 | < 0.12 | 0.5 |
| plasmid KPC-33n6 in naïve E. coli Top10 | KPC-33 | D179Y | R6H F20L | < 8 | 16 | < 8 | 8 | 8 | 8 | 16 | < 1 | > 128 | 64 | 2 | < 1 | < 0.5 | < 4 | < 0.12 | 2 |
AMP, Ampicillin ; CEP, Cephalothin, FAZ, Ceftazolin ; FOX, Cefoxitin ; AXO, Ceftriaxone ; CTX, Cefotaxime ; POD, Cefpodoxime ; FEP, Cefepime ; CAZ, Ceftazidime ; CZA; Ceftazidime-avibactam ; T/C, Ceftazdime/clavulanate ; MEM, Meropenem ; IMP, Imipenem ; PTZ, Piperacillin/tazobactam ; F/C, Cefotaxime/clavulanate; FDC, Cefiderocol.